Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC)., Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.

Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

2.

Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.

Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, Devereux H, Deayton J, Dykhoff A, Lipman MC, Phillips AN, Johnson MA.

J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):401-7.

PMID:
10458621
3.

Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.

Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR.

AIDS Patient Care STDS. 2010 May;24(5):279-86. doi: 10.1089/apc.2009.0283.

4.

Differential impact of combined antiretroviral therapy on the survival of italian patients with specific AIDS-defining illnesses.

Conti S, Masocco M, Pezzotti P, Toccaceli V, Vichi M, Boros S, Urciuoli R, Valdarchi C, Rezza G.

J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8.

PMID:
11141245
5.

[AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].

Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligoi B.

Epidemiol Prev. 2009 Jul-Oct;33(4-5):184-9. Italian.

6.
7.

Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons--San Francisco, 1981-2012.

Djawe K, Buchacz K, Hsu L, Chen MJ, Selik RM, Rose C, Williams T, Brooks JT, Schwarcz S.

J Infect Dis. 2015 Nov 1;212(9):1366-75. doi: 10.1093/infdis/jiv235. Epub 2015 Jun 3.

PMID:
26044289
8.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.

PMID:
10605973
9.

Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.

Mocroft AJ, Lundgren JD, d'Armino Monforte A, Ledergerber B, Barton SE, Vella S, Katlama C, Gerstoft J, Pedersen C, Phillips AN.

Int J Epidemiol. 1997 Apr;26(2):400-7.

PMID:
9169177
10.

The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy.

Welch K, Morse A; Adult Spectrum of Disease Project in New Orleans..

AIDS Patient Care STDS. 2002 Feb;16(2):75-81.

PMID:
11874639
11.

Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.

Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV..

HIV Med. 2008 Apr;9(4):246-56. doi: 10.1111/j.1468-1293.2008.00554.x.

12.
13.

Impact of opportunistic disease on survival in patients with HIV infection.

Chaisson RE, Gallant JE, Keruly JC, Moore RD.

AIDS. 1998 Jan 1;12(1):29-33.

PMID:
9456252
14.

Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.

Antiretroviral Therapy Cohort Collaboration (ART-CC)., Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR.

AIDS. 2013 May 15;27(8):1321-9. doi: 10.1097/QAD.0b013e32835faa95.

15.

Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.

Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM.

Clin Infect Dis. 2012 Feb 1;54(3):424-33. doi: 10.1093/cid/cir802. Epub 2011 Nov 17.

16.

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.

Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS.

CMAJ. 1999 Mar 9;160(5):659-65.

17.

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS.

JAMA. 1998 Feb 11;279(6):450-4.

PMID:
9466638
18.

Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT; Swiss HIV Cohort Study..

Antivir Ther. 2007;12(6):931-9.

PMID:
17926647
19.
20.

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker S, Porter K, Sabin C, Chêne G.

AIDS. 2009 Aug 24;23(13):1743-53. doi: 10.1097/QAD.0b013e32832e9b78.

Supplemental Content

Support Center